These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15758648)

  • 1. Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension.
    Hernández-Guerra M; García-Pagán JC; Bosch J
    J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S131-7. PubMed ID: 15758648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiology and a Rational Basis of Therapy.
    Gracia-Sancho J; Maeso-Díaz R; Bosch J
    Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic management of portal hypertension.
    Berzigotti A; Bosch J
    Clin Liver Dis; 2014 May; 18(2):303-17. PubMed ID: 24679496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Laleman W; Van Landeghem L; Van der Elst I; Zeegers M; Fevery J; Nevens F
    Gastroenterology; 2007 Feb; 132(2):709-19. PubMed ID: 17258737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide and portal hypertension.
    González-Abraldes J; García-Pagán JC; Bosch J
    Metab Brain Dis; 2002 Dec; 17(4):311-24. PubMed ID: 12602508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A; Hernández-Gea V; Bosch J
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver.
    Fiorucci S; Antonelli E; Morelli A
    Dig Liver Dis; 2003 May; 35 Suppl 2():S61-9. PubMed ID: 12846445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.
    Bosch J; Abraldes JG; Fernández M; García-Pagán JC
    J Hepatol; 2010 Sep; 53(3):558-67. PubMed ID: 20561700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of portal hypertension with NCX-1000, a liver-specific NO donor. A review of its current status.
    Fiorucci S; Antonelli E; Tocchetti P; Morelli A
    Cardiovasc Drug Rev; 2004; 22(2):135-46. PubMed ID: 15179450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and portal hypertension: a new pharmacological challenge.
    Ramírez G; Briceño J; Rojas A
    Curr Vasc Pharmacol; 2012 Nov; 10(6):767-72. PubMed ID: 22272892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The application of non-selective β-blockers, angiotensin receptor antagonists and statins in liver cirrhotic patients].
    Zhang XX; Guo JS
    Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):923-928. PubMed ID: 31941254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pharmacological modulation of portal hypertension syndrome: current status and future prospects].
    González García M; Albillos Martínez A
    Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():1-7. PubMed ID: 15195528
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of simvastatin on the portal-systemic collateral vascular response to endothelin-1 and shunting degree in portal hypertensive rats.
    Hsu SJ; Wang SS; Hsin IF; Huang HC; Lee FY; Lee JY; Lin HC; Chuang CL; Lee SD
    Scand J Gastroenterol; 2013 Jul; 48(7):831-8. PubMed ID: 23672611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamics in the isolated cirrhotic liver.
    Zipprich A
    J Clin Gastroenterol; 2007; 41 Suppl 3():S254-8. PubMed ID: 17975473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment update on portal hypertension and complications].
    Lee JW
    Korean J Gastroenterol; 2010 Sep; 56(3):144-54. PubMed ID: 20847605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiology of portal hypertension.
    Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New cellular and molecular targets for the treatment of portal hypertension.
    Gracia-Sancho J; Maeso-Díaz R; Fernández-Iglesias A; Navarro-Zornoza M; Bosch J
    Hepatol Int; 2015 Apr; 9(2):183-91. PubMed ID: 25788198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vasodilator agents in portal hypertension].
    Combis JM; Vinel JP
    Gastroenterol Clin Biol; 1991; 15(12):881-7. PubMed ID: 1686004
    [No Abstract]   [Full Text] [Related]  

  • 19. Portal hypertension: from pathophysiology to clinical practice.
    Laleman W; Landeghem L; Wilmer A; Fevery J; Nevens F
    Liver Int; 2005 Dec; 25(6):1079-90. PubMed ID: 16343056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.
    Grace JA; Klein S; Herath CB; Granzow M; Schierwagen R; Masing N; Walther T; Sauerbruch T; Burrell LM; Angus PW; Trebicka J
    Gastroenterology; 2013 Oct; 145(4):874-884.e5. PubMed ID: 23796456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.